Economic Incentives in Clinical Investigation

New England Journal of Medicine

Volumn 320, Issue 14, 1989, Pages 933-934

  Relman, Arnold S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; ECONOMIC ASPECT; ECONOMICS; EDITORIAL; MARKETING; MEDICAL ETHICS; MEDICAL RESEARCH; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL;

EID: 0024558207     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198904063201410     Document Type: Editorial

References (7)

1. Relman AS. The new medical-industrial complex. N Engl J Med 1980; 303: 963–70.
2. Relman Dealing with conflicts of interest. N Engl J Med 1985; 313: 749–51.
3. Relman Medicine as a profession and a business. In: McMurrin SM, ed. The Tanner lectures on human values. Vol. 8. Salt Lake City: The University of Utah Press, 1988:283–313.
4. Relman. Dealing with conflicts of interest. N Engl J Med 1984; 310: 1182–3.
5. Chase M. Mixing science, stocks, raises question of bias in the testing of drugs. Wall Street Journal. January 26, 1989: 1.
6. Healy B, Campeau L, Gray R, et al. Conflict-of-interest guidelines for a multicenter clinical trial of treatment after coronary-artery bypass-graft surgery. N Engl J Med 1989; 320: 949–51.
7. National Institutes of Health Guide for Grants and Contracts. Bethesda, Md.: National Institutes of Health, 1989:1.